98%
921
2 minutes
20
Background And Aims: Both fibrosis status and body weight are important for assessing prognosis in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to identify population clusters for specific clinical outcomes based on fibrosis-4 (FIB-4) index and body mass index (BMI) using an unsupervised machine learning method.
Methods: We conducted a multicenter study of 1335 biopsy-proven NAFLD patients from Japan. Using the Gaussian mixture model to divide the cohort into clusters based on FIB-4 index and BMI, we investigated prognosis for these clusters.
Results: The cohort consisted of 223 cases (16.0%) with advanced fibrosis (F3-4) as assessed from liver biopsy. Median values of BMI and FIB-4 index were 27.3 kg/m and 1.67. The patients were divided into four clusters by Bayesian information criterion, and all-cause mortality was highest in cluster d, followed by cluster b (P = 0.001). Regarding the characteristics of each cluster, clusters d and b presented a high FIB-4 index (median 5.23 and 2.23), cluster a presented the lowest FIB-4 index (median 0.78), and cluster c was associated with moderate FIB-4 level (median 1.30) and highest BMI (median 34.3 kg/m ). Clusters a and c had lower mortality rates than clusters b and d. However, all-cause of death in clusters a and c was unrelated to liver disease.
Conclusions: Our clustering approach found that the FIB-4 index is an important predictor of mortality in NAFLD patients regardless of BMI. Additionally, non-liver-related diseases were identified as the causes of death in NAFLD patients with low FIB-4 index.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jgh.16326 | DOI Listing |
Clin Transl Gastroenterol
September 2025
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China.
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease worldwide. It is now updated as metabolic dysfunction-associated steatotic liver disease (MASLD). The progression of MASLD to hepatocellular carcinoma (HCC) involves complex mechanisms, with the gut microbiota and its metabolites playing a pivotal role in this transformation through the "gut-liver axis.
View Article and Find Full Text PDFExplore (NY)
August 2025
Dept. of Ilaj bit Tadbeer, School of Unani Medical Education and Research, Jamia Hamdard, New Delhi, India. Electronic address:
Introduction: Non-alcoholic Fatty Liver Disease (NAFLD) is a global health concern, and leading cause of liver cirrhosis and carcinoma, with no approved treatment till date. In Unani medicine, the management of fat deposition in liver is done with mufatteḥ-i-sudad (de-obstruent) and muḥallil-i-waram (anti-inflammatory) drugs, to expel morbid matter and restore hepatic functions. This study was done to evaluate the efficacy of Unani drugs in NAFLD on specific biochemical and radiological parameters.
View Article and Find Full Text PDFClin Exp Gastroenterol
August 2025
Biomedical Research Center, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam.
Background: Non-alcoholic fatty liver disease (NAFLD) is an increasing public health concern in Vietnam, particularly among working-age adults (18-60 years). The rs738409 variant (C>G) is a well-established risk factor for NAFLD globally; however, its impact on the Vietnamese population remains inadequately studied. This study investigates its association with NAFLD risk and its interaction with metabolic factors.
View Article and Find Full Text PDFClin Exp Hepatol
June 2025
Department of Obesity Treatment, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, Poznan, Poland.
The number of patients whose chronic metabolic liver disease leads to the development of hepatocellular carcinoma (HCC) is increasing. In patients with non-alcoholic fatty liver disease (NAFLD), HCC can arise in both cirrhotic and non-cirrhotic livers. This complicates appropriate surveillance and causes HCC to be diagnosed at a more advanced stage.
View Article and Find Full Text PDFClin Exp Hepatol
June 2025
Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Aim Of The Study: Chronic hepatitis C (CHC) infection remains one of the most prevalent chronic liver disease worldwide. A sustained virological response (SVR) can be achieved at high rates for CHC patients receiving direct-acting antivirals (DAAs). However, even small subsets of patients achieving SVR still have a risk of developing hepatocellular carcinoma (HCC).
View Article and Find Full Text PDF